2017 Annual Report
Amicus Brief Filed in RPX Corp. v. Chanbond LLC: Patient and public interest actors should have the same rights as drugmakers to appeal IPR decisions to the courts to prevent unmerited patents.
Submission to Health and Human Services: I-MAK response to Blueprint to Lower Drug Prices
Letter to the USPTO Director
Policy Prescriptions to Solve the Drug Patent Problem
Submission to Chinese FDA: more exclusivity will harm patients
About I-MAK
Over 85% of Patients Diagnosed with Chronic Hepatitis C in the U.S. Are Currently NOT Receiving Treatment
The Roadmap Special Edition Report on Tenofovir Alafenamide Fumarate: April 2018
This report expands on the information provided in the original Roadmap, and most importantly, aims to provide the international community with critical analysis well in advance of when policy-makers will have to determine how TAF may be used in HIV treatment programs.
Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind
Worldwide, 71 million people are infected with hepatitis C virus (HCV), which, without treatment, can lead to liver failure or hepatocellular carcinoma. HCV co-infection increases liver- and AIDS-related morbidity and mortality among HIV-positive people, despite ART. A 12-week course of HCV direct-acting antivirals (DAAs) usually cures HCV – regardless of HIV status. However, patents and…